Skip to main navigation Skip to search Skip to main content

Quality of life in long-term survivors of marrow transplantation: Comparison with a matched group receiving maintenance chemotherapy

  • A. Molassiotis
  • , O. B A Van Den Akker
  • , D. W. Milligan
  • , J. M. Goldman
  • , B. J. Boughton
  • , J. A. Holmes
  • , S. Thomas

    Research output: Contribution to journalArticlepeer-review

    Abstract

    A retrospective descriptive study was designed to assess the quality of life (QoL) and psychosocial adjustment in long-term BMT survivors compared with a group of patients with haematological malignancies receiving maintenance chemotherapy (MC), matched for age, post-treatment time, sociodemographic and disease characteristics. The sample consisted of 91 long-term BMT survivors and 73 MC patients from three teaching hospitals in the UK. The results indicated that most of the BMT subjects had a good to excellent quality of life and, in some domains, even better adjustment than the MC patients. However, 20% of the BMT subjects had failed to return to full-time employment at a mean post-BMT time of almost 40 months. A significant number of BMT subjects were also identified with symptoms of anxiety and depression. The physical symptomatology had an association with psychological status. Impotence-related difficulties, decreased sexual satisfaction and altered body image were the main characteristics of psychosexual dysfunction in the BMT group. Poorer quality of life was predicted by the presence of depressive symptoms, low affirmation, and impoverished social adjustment.
    Original languageEnglish
    Pages (from-to)249-258
    Number of pages9
    JournalBone Marrow Transplantation
    Volume17
    Issue number2
    Publication statusPublished - Feb 1996

    Keywords

    • Adjustment
    • BMT
    • Long-term survivors
    • Quality of life

    Fingerprint

    Dive into the research topics of 'Quality of life in long-term survivors of marrow transplantation: Comparison with a matched group receiving maintenance chemotherapy'. Together they form a unique fingerprint.

    Cite this